AstraZeneca PLC / Neogene Therapeutics B.V.

Solid Tumors (Neoantigen TCR-T Cell Therapy)

700K US cases/yr · $15.0B Global cell and gene therapy market 2022 · ~$320M Total deal value (up to, incl. contingent consideration)

Disease Overview

The AstraZeneca-Neogene acquisition adds next-generation T-cell receptor T-cell (TCR-T) therapy capabilities targeting solid tumor indications driven by shared neoantigens — most notably mutant KRAS (mKRAS, present in ~30% of NSCLC, ~90% of pancreatic, ~45% of colorectal cancers) and mutant TP53 (mTP53, present in ~50% of all solid tumors). The U.S. addressable population is approximately 700,000 new mKRAS or mTP53 solid tumor cases annually. Solid tumor cell therapy is the next frontier after CAR-T's success in heme malignancies — to date, no autologous TCR-T or CAR-T therapy has been approved for common solid tumors, though Adaptimmune's afamitresgene autoleucel (afami-cel, KIMMTRAK precedent for synovial sarcoma) earned 2024 FDA approval for synovial sarcoma. The Neogene platform is differentiated by its individualized TCR discovery from patient tumor-infiltrating lymphocytes plus shared-neoantigen TCR libraries (off-the-shelf for HLA-matched patients). AstraZeneca paid $200M upfront plus up to $120M contingent for early/preclinical assets, deliberately aiming to build solid-tumor cell therapy capability ahead of clinical proof-of-concept. Pricing benchmarks for autologous cell therapy in heme are $400K-$500K per infusion; solid-tumor TCR-T pricing post-approval is expected to be in similar range.

Competitive Landscape

The solid tumor TCR-T and adoptive cell therapy landscape spans autologous and off-the-shelf platforms. Tebentafusp (Kimmtrak, Immunocore) is the first-approved bispecific TCR (gp100xCD3) in metastatic uveal melanoma — not autologous TCR-T but the closest TCR validation in solid tumors. Afami-cel (Adaptimmune, MAGE-A4) is on track for first solid-tumor TCR-T approval in synovial sarcoma. mKRAS-directed TCR-T entrants include Affini-T Therapeutics (mKRAS G12V/G12D Phase 1), TScan Therapeutics (TSC-100/101 in HLA-mismatch leukemia post-HCT, plus mTAA platform), and Iovance Biotherapeutics' lifileucel (Amtagvi, TIL therapy approved 2024 in melanoma). Off-the-shelf platforms include Allogene (allogeneic CAR-T), Moderna's individualized neoantigen vaccines (mRNA-4157 with Keytruda in melanoma), and Gritstone Bio's neoantigen vaccines. AstraZeneca's Neogene acquisition positions AZ alongside Bristol's bluebird/Mosaic 2seventy heme cell therapy bench plus Roche's TCR-T platform via Adaptimmune partnership — a small but strategically critical capability buy ahead of clinical readouts.